Group 1 - Morgan Stanley's research report indicates that the inclusion of Eli Lilly's tirzepatide in the medical insurance directory is not entirely surprising, and believes that Innovent Biologics' mazdutide can adopt flexible pricing strategies to respond [1] - The report highlights the vast market potential for weight loss drugs in China, suggesting that there is enough space for the development of multiple blockbuster drugs [1] - The firm has assigned an "Overweight" rating to Innovent Biologics with a target price of HKD 110, expressing optimism about its product pipeline that spans oncology, autoimmune diseases, metabolic disorders, and ophthalmology [1] Group 2 - The report anticipates that by 2027, Innovent Biologics will have over ten products on the market, with projected sales reaching RMB 17 billion [1]